Hydroxycarbamide

Drug Profile

Hydroxycarbamide

Alternative Names: Droxia; Hydrea; Hydroxyurea; Litalir; NSC 32065; OncoCarbide; SQ 1089; WR 83799

Latest Information Update: 24 Jan 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Barr Laboratories; Bristol-Myers Squibb
  • Developer Barr Laboratories; Bristol-Myers Squibb; Teva Pharmaceutical Industries
  • Class Antianaemics; Antineoplastics; Small molecules; Urea compounds
  • Mechanism of Action Ribonucleotide reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cancer; Sickle cell anaemia
  • Discontinued HIV infections

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis
  • 10 Jul 2000 FDA approval for 250mg capsule for cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top